** Shares in Sartorius SATG.DE were down around 7% in
Frankfurt early trade after the pharmaceutical equipment
supplier cut its full-year guidance
** The guidance cut was "much worse than expected", a local
trader says after the company lowered outlook on sales and
earnings margins for 2024
** The company cited "continuing subdued demand", reporting
a 2.2% decline in sales revenue in the first six months of the
year
** Sartorius' French unit Sartorius Stedim Biotech
STDM.PA also cut its guidance, its shares are indicated down
4% according to LSEG data
(Reporting by Marleen Kaesebier)
((Marleen.kaesebier@thomsonreuters.com))